title: Gemcitabine plus cisplatin for the treatment of metastatic breast cancer.
abstract: The combination of gemcitabine and cisplatin has proven effective as first-line chemotherapy for patients with breast cancer, inducing a response rate of 80% in one phase II study. Five additional studies in intensively pretreated breast cancer patients demonstrated a median response rate of 43% (range, 26%-50%). The toxicity profile was moderate, with thrombocytopenia and neutropenia as the main side effects. The gemcitabine/ cisplatin combination, therefore, offers a tolerable and effective treatment option, particularly for patients whose disease progressed after treatment with anthracyclines and/or taxanes.
authors.affiliation: Klinikum Grosshadern, Munich, Germany. volker.heinemann@med3.med.uni-muenchen.de
authors.forename: Volker
authors.initials: V
authors.lastname: Heinemann
mesh_terms: D018943:Anthracyclines; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D001952:Bridged-Ring Compounds; D002945:Cisplatin / Q000008:administration & dosage; D017322:Clinical Trials, Phase II as Topic; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D009362:Neoplasm Metastasis; D043823:Taxoids; D000068878:Trastuzumab; D017211:Treatment Failure; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D018943:Anthracyclines; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001952:Bridged-Ring Compounds; D043823:Taxoids; D003841:Deoxycytidine; C080625:taxane; D000068878:Trastuzumab; D002945:Cisplatin; D000093542:Gemcitabine